Opportunity Information: Apply for EDS EDS 24 001
The Emergency Department Substance Use Surveillance System grant opportunity (Funding Opportunity Number: EDS EDS 24 001) is a discretionary cooperative agreement offered by the Office of National Drug Control Policy (ONDCP) to strengthen early warning surveillance for emerging and changing drug threats in the United States. The core idea is to build a faster, more cost-effective way to detect shifts in illicit drug exposure by taking advantage of urine specimens that hospitals already collect under routine care and testing protocols, especially in emergency departments, trauma units, and other hospital settings where biological samples are commonly obtained. Instead of collecting new specimens from scratch, the project focuses on re-testing specimens that have already been collected and initially tested, using broader and more current drug panels right before the specimens would otherwise be discarded.
The methodology being expanded was first developed in local criminal justice settings, where urine testing is already common for people in pre-trial or lock-up, individuals on probation or parole, and drug court participants. ONDCP views this approach as promising for hospital-based populations because emergency departments often serve as a front-line point of contact for overdoses, intoxications, injuries, and other acute events linked to substance use. By re-testing previously collected urine with an expanded drug panel, the project aims to identify which substances are being detected, which are being missed by conventional testing, and how drug patterns differ across subpopulations and geographic areas. The expanded panel explicitly includes high-priority and rapidly evolving threats such as xylazine, fentanyl, methamphetamine, and other new psychoactive substances (NPS), with the broader goal of capturing both established and newly emerging drugs that may not be included in standard hospital toxicology screens.
A key value of the approach is efficiency and timeliness. Because the specimens were already collected and tested, the project can bypass much of the cost, logistical complexity, and delay associated with new sample collection. Re-using specimens with known initial test results also makes it possible to compare what traditional protocols show versus what enhanced testing reveals, generating practical evidence about gaps in existing testing standards. The expected outcome is a more accurate, near-real-time snapshot of emerging drug presence in specific patient populations and localities, which can support earlier detection of new substances, changing mixtures (such as fentanyl combined with xylazine), and shifting patterns of stimulant and opioid use.
Beyond laboratory re-testing, the opportunity also requires integrating results into a broader public health and surveillance context using hospital data and de-identified, nationally representative patient electronic health records (EHRs). The intent is to connect urine positivity findings with information about clinical outcomes and consequences of exposure at regional and national scales, helping distinguish whether changes seen in testing correspond to changes in emergency presentations, overdoses, complications, or other measurable harms. In practice, this means using EHR-based analysis to interpret and validate what the lab findings suggest, providing a fuller picture of drug exposure trends and their real-world impacts in healthcare settings.
ONDCPs larger objective is to apply and scale this combined model of enhanced urine re-testing plus EHR analysis across multiple locations throughout the country. The anticipated benefits include reinforcing best-practice guidelines for toxicology testing, supporting greater standardization in what hospitals test for and how results are interpreted, and building both local and national surveillance capacity. In other words, the project is not only about generating new data, but also about improving the systems and guidance that help hospitals and public health partners recognize emerging threats sooner and respond more effectively.
The opportunity makes a single award (Expected Awards: 1) with an award ceiling of $150,000. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations with 501(c)(3) status (other than institutions of higher education). The closing date listed is 2024-09-17, and the CFDA number associated with the program is 95.007.Apply for EDS EDS 24 001
- The Office of National Drug Control Policy in the health sector is offering a public funding opportunity titled "Emergency Department Substance Use Surveillance System" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 95.007.
- This funding opportunity was created on 2024-09-10.
- Applicants must submit their applications by 2024-09-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Public and State controlled institutions of higher education, Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the Emergency Department Substance Use Surveillance System grant?
The Emergency Department Substance Use Surveillance System grant (Funding Opportunity Number: EDS EDS 24 001) is a discretionary cooperative agreement offered by the Office of National Drug Control Policy (ONDCP). Its purpose is to strengthen early warning surveillance for emerging and changing drug threats in the United States.
What problem is this funding opportunity trying to solve?
The opportunity targets gaps in how quickly and accurately drug threats can be detected as they evolve. Conventional hospital toxicology testing may not include newer or rapidly changing substances, and new specimen collection can be expensive and slow. This project is designed to produce a faster, more cost-effective way to identify shifts in illicit drug exposure.
What is the core approach or method being funded?
The core method is to re-test urine specimens that hospitals already collect under routine care and testing protocols. Rather than collecting new specimens, the project focuses on re-testing specimens that were already collected and initially tested, using broader and more current drug panels before the specimens would otherwise be discarded.
Which hospital settings are emphasized for specimen availability?
The opportunity highlights emergency departments in particular, along with trauma units and other hospital settings where biological samples are commonly obtained. Emergency departments are emphasized because they are often a front-line point of contact for overdoses, intoxications, injuries, and other acute events linked to substance use.
Why re-test specimens instead of collecting new samples?
Re-testing previously collected specimens is intended to improve efficiency and timeliness. Because the specimens were already collected and tested, the project can avoid much of the cost, logistical complexity, and delay that come with collecting new samples.
How does this method help improve surveillance compared to standard hospital testing?
Because the specimens have known initial test results, enhanced re-testing allows comparisons between what traditional hospital testing detects and what broader, updated panels reveal. This helps identify which substances are being detected, which are being missed by conventional testing, and where testing standards may have gaps.
What substances are specifically mentioned as priorities for the expanded drug panels?
The expanded drug panel explicitly includes high-priority and rapidly evolving threats such as xylazine, fentanyl, methamphetamine, and other new psychoactive substances (NPS). The broader goal is to capture both established and newly emerging drugs that may not be included in standard hospital toxicology screens.
What kinds of insights is the project expected to generate?
The project aims to produce a more accurate, near-real-time snapshot of emerging drug presence in specific patient populations and localities. It is intended to support earlier detection of new substances, changing drug mixtures (for example, fentanyl combined with xylazine), and shifting patterns of stimulant and opioid use.
How does geography or population subgroup analysis fit into the project?
The opportunity describes using re-testing to understand how drug patterns differ across subpopulations and geographic areas. By expanding what is tested for, the surveillance system can better detect differences in exposure patterns across locations and patient groups represented in hospital settings.
What is the role of electronic health records (EHRs) in this grant?
Beyond laboratory re-testing, the opportunity requires integrating results into a broader public health and surveillance context using hospital data and de-identified, nationally representative patient electronic health records (EHRs). The intent is to connect urine positivity findings with clinical outcomes and consequences of exposure at regional and national scales.
How are EHRs expected to complement the lab re-testing results?
EHR-based analysis is intended to help interpret and validate what the laboratory findings suggest. Specifically, the grant aims to determine whether changes seen in testing correspond to changes in emergency presentations, overdoses, complications, or other measurable harms in healthcare settings.
What is ONDCP ultimately trying to build or scale with this work?
ONDCPs larger objective is to apply and scale the combined model of enhanced urine re-testing plus EHR analysis across multiple locations throughout the country. The goal is to build stronger local and national surveillance capacity for emerging drug threats.
How could the project influence hospital toxicology practices?
The anticipated benefits include reinforcing best-practice guidelines for toxicology testing and supporting greater standardization in what hospitals test for and how results are interpreted. The approach is designed to generate practical evidence about gaps in existing testing standards.
Is this a grant or a cooperative agreement?
This opportunity is described as a discretionary cooperative agreement.
How many awards does ONDCP expect to make under this opportunity?
ONDCP expects to make a single award (Expected Awards: 1).
What is the maximum funding amount available?
The award ceiling is $150,000.
Who is eligible to apply?
Eligible applicants include:
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Nonprofit organizations with 501(c)(3) status (other than institutions of higher education)
What is the application closing date?
The closing date listed for this opportunity is 2024-09-17.
What is the CFDA number associated with this program?
The CFDA number associated with the program is 95.007.
What is the main public health value of using hospital-based urine specimens?
Hospital settings, especially emergency departments, may capture early signals of emerging drug threats because they receive patients experiencing overdoses, intoxications, injuries, and other acute outcomes. Re-testing urine already collected under routine care can provide timely information on what substances are present and changing.
How does the opportunity define "early warning" in practical terms?
Based on the description, "early warning" is supported by near-real-time detection of emerging drug presence through efficient re-testing of existing specimens with expanded panels, paired with EHR-based analysis to understand related clinical consequences.
What makes this approach "more cost-effective" according to the opportunity description?
The cost-effectiveness comes from taking advantage of urine specimens already collected and initially tested as part of routine hospital care. This reduces the need for new specimen collection workflows and enables faster turnaround by working with specimens that would otherwise be discarded.
What is being compared when specimens are re-tested?
The project compares the substances detected under traditional hospital testing protocols with the substances detected using an expanded and more current drug panel. This comparison is intended to highlight detection gaps and reveal newly emerging or previously untested substances.
Browse more opportunities from the same category: Health
Next opportunity: SOI - Non-Federal Match/Cost-Share for Other Federal Infrastructure Grants
Previous opportunity: Advanced Rehabilitation Research Training (ARRT) Program - Employment
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for EDS EDS 24 001
Applicants also applied for:
Applicants who have applied for this opportunity (EDS EDS 24 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required) Apply for PAR 24 275 Funding Number: PAR 24 275 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Coordinating Center to Support Consortium for Neuroscience Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research in Low- and Middle-Income Countries (LMICs) (U24 Clinical Trial Not Allowed) Apply for RFA AG 25 014 Funding Number: RFA AG 25 014 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Health Systems Strengthening (HSS) Activity Apply for 72038624RFA00004 Funding Number: 72038624RFA00004 Agency: India USAID-New Delhi Category: Health Funding Amount: $20,000,000 |
| Research Centers in Minority Institutions (RCMI) (U54 - Clinical Trial Optional) Apply for RFA MD 24 012 Funding Number: RFA MD 24 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID Accelerator Activity Apply for 72066024RFA00006 Funding Number: 72066024RFA00006 Agency: Democratic Republic of the Congo USAID-Kinshasa Category: Health Funding Amount: $90,500,000 |
| USAID Multi Sector Nutrition in the Democractic Republic of Congo Apply for 72066024RFI00007 Funding Number: 72066024RFI00007 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| Early Psychosis Intervention Network (EPINET): Learning Health Care Research to Improve Mental Health Services and Outcomes (P01 Clinical Trial Optional) Apply for RFA MH 25 200 Funding Number: RFA MH 25 200 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed) Apply for RFA AI 24 065 Funding Number: RFA AI 24 065 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Coordinating Center (NCC) for AHRQs Healthcare Extension Service - State-based Solutions to Healthcare Improvement (U54) Apply for RFA HS 24 006 Funding Number: RFA HS 24 006 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) Apply for RFA NS 25 024 Funding Number: RFA NS 25 024 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Evaluation Center (NEC) for AHRQs Healthcare Extension Service: State-based Solutions to Healthcare Improvement (U19) Apply for RFA HS 24 005 Funding Number: RFA HS 24 005 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Global Health Security (GHS) Activity Apply for 72039124RFA00002 Funding Number: 72039124RFA00002 Agency: Pakistan USAID-Islamabad Category: Health Funding Amount: $43,000,000 |
| Biomedical Research Facilities (C06 Clinical Trial Not Allowed) Apply for PAR 25 061 Funding Number: PAR 25 061 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) Apply for PAR 25 055 Funding Number: PAR 25 055 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Experiences and/or Mentoring Networks through Research Education to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed) Apply for PAR 25 020 Funding Number: PAR 25 020 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional) Apply for PAR 25 050 Funding Number: PAR 25 050 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed) Apply for PA 25 093 Funding Number: PA 25 093 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers on the Demography and Economics of Aging and Alzheimers Disease and Alzheimers Disease-Related Dementias Coordinating Center (U24 Clinical Trial Optional) Apply for RFA AG 25 008 Funding Number: RFA AG 25 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers for Precision Disease Modeling (U54) (Clinical Trials Not Allowed) Apply for PAR 24 305 Funding Number: PAR 24 305 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed) Apply for RFA AI 24 067 Funding Number: RFA AI 24 067 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "EDS EDS 24 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.